Compare TC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TC | MGNX |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.8M | 220.6M |
| IPO Year | 2018 | 2013 |
| Metric | TC | MGNX |
|---|---|---|
| Price | $1.55 | $4.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 9.7K | ★ 1.2M |
| Earning Date | 03-28-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $1.26 |
| 52 Week High | $19.99 | $5.08 |
| Indicator | TC | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 13.07 | 62.12 |
| Support Level | $0.53 | $1.49 |
| Resistance Level | $11.40 | N/A |
| Average True Range (ATR) | 1.06 | 0.33 |
| MACD | -0.53 | 0.05 |
| Stochastic Oscillator | 0.98 | 70.08 |
Token Cat Ltd has two reportable business segments: automotive electronics resale business and advertising business. The automotive electronics resale business focuses on sourcing, holding, and reselling automotive electronics products, and includes sales of automotive electronic component equipment and accessories, mainly consisting of communication device and power module. The Company procures products from third-party suppliers and resells them to customers through its sales channels. The advertising business currently consists mainly of proxy advertising services, through which the Company helps clients promote their brands, services and products on third-party online platforms. The automotive electronics resale business segment generates maximum revenue.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.